



Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors

KIRKLAND, WA., March 7, 2008 - Pathway Medical Technologies, which is developing innovative medical devices for the treatment of arterial disease, announced that Paul Buckman has been named as the new Chairman of the Board of Directors. He replaces Dan Galles, who has been acting Board Chairman since late 2006.

"We are very pleased Paul has accepted the role of Chairman. He brings an extensive range of industry experience to the Pathway board, including early commercialization experience. This is especially important to the company as it prepares for the launch of its first product, the Pathway PV™ Atherectomy System." said Galles.

"Since Paul joined our Board in 2007, he has become a real asset. His deep commercial experience with a variety of companies has already proven useful," said Tom Clement, Pathway President and CEO, "and I expect in his new role, Paul's vision and leadership will continue to benefit both the company and the patients who will be treated with our device."

Buckman, who has worked in the medical device industry for over 30 years, is currently CEO and a director of Devax, Inc., a development-stage cardiovascular device company. He joined Devax in 2006 from St. Jude Medical, Inc. where he was an executive officer and President of its Cardiology Division. Before St. Jude Medical, Buckman served as Chairman of the Board of Directors and CEO of ev3, LLC, which he co-founded. Earlier in his career he was with Boston Scientific Corporation, where he held several executive positions before being named President of the Scimed Division. In the course of his career, Buckman has served on the Board of a variety of companies, including: EndiCor, Inc., Microvena, Inc., Micro Therapeutics, Inc., and Velocimed, Inc., which he also co-founded.

About Pathway Medical Technologies, Inc.

Pathway Medical Technologies, Inc. was founded to design, market and manufacture medical devices for the treatment of arterial disease. The company's initial focus is treating peripheral arterial disease (PAD) more quickly, safely and effectively than existing technologies. An estimated 8-12 million people are afflicted by PAD in the U.S., and that number is projected to grow to over 20 million during the next 10 years. The company's Pathway PV™ Atherectomy System allows for a minimally invasive procedure designed to restore circulation in the peripheral arteries by removing both hard and soft diseased tissue. For further information, visit the company's Web site at www.pathwaymedical.com.

Company Contact:

Thomas J. Clement, CEO/President

Tel: (425) 636-4122

clementt@pathwaymedical.com